SFDA Suspends European Pharmaceutical Factory Due to Critical Manufacturing Violations
2025-07-14
The Saudi Food and Drug Authority (SFDA) has announced the suspension of a European pharmaceutical factory's registration. This decisive action follows an inspection, part of the SFDA's external monitoring program, which uncovered critical and fundamental violations of Good Manufacturing Practices (GMP). The suspension highlights the SFDA's commitment to safeguarding public health and ensuring the safety and quality of medicines available in Saudi Arabia.